ABSTRACT
Background Breast arterial calcification (BAC), visible on mammograms, has emerged as a biomarker of cardiovascular disease (CVD) in women. Barriers to clinical implementation of BAC include limited studies with clinical outcomes and lack of quantification tools.
Methods This single-center, retrospective study included women with a screening digital mammogram from 2008-2016. BAC was quantified using an automated, artificial intelligence (AI)-generated Bradley score, as a binary (Bradley score ≥5) and continuous variable. Clinical outcomes were determined via electronic medical records. Regression analyses were used to evaluate the association between BAC and outcomes of mortality and a composite of acute myocardial infarction, heart failure, stroke, and mortality. Models were adjusted for age, race, diabetes, smoking status, blood pressure, cholesterol, and history of CVD and chronic kidney disease.
Results A total of 18,092 women were included with a mean age 56.8±11.0 years. Prevalence of comorbidities included diabetes (13%), hypertension (36%), hyperlipidemia (40%) and smoking (5%). BAC was present in 4,223 (23%). Over a median follow-up of 6 years, death occurred in 7.8% women with and 2.3% women without BAC. The composite outcome occurred in 12.4% of women with and 4.3% of women without BAC. Compared to those without, women with BAC had adjusted hazard ratios (aHR) of 1.49 (95% CI 1.33-1.67) for mortality and 1.56 (1.41-1.72) for the composite endpoint, after accounting for traditional risk factors. With a continuous BAC score, each 10-point increase was associated with higher risk of mortality (1.08 [1.06-1.11]) and the composite endpoint (1.08 [1.06-1.10]). BAC was especially predictive of future events among younger women.
Conclusion BAC is significantly and independently associated with mortality and incident CVD, especially among younger women. Measuring BAC using an AI algorithm is feasible and clinically relevant. Further studies are needed to confirm these findings and to evaluate whether interventions guided by BAC improve outcomes.
What is new?
Breast arterial calcification (BAC) on mammograms can be reliably quantified using a novel software based on an artificial intelligence (AI) algorithm.
BAC is independently associated with an increased risk of all-cause mortality and cardiovascular outcomes. These associations held true when looking at BAC as presence, score quartile, and as a continuous value as well as after accounting for traditional cardiovascular risk factors.
In stratification analysis, BAC was most predictive of all-cause mortality and cardiovascular outcomes among younger women (age 40-59 years), but still independently predictive in women aged 60-74 years.
What are the clinical implications?
Our data provide support for the inclusion of BAC findings on mammogram reports.
Automated quantification tools and reporting methods of BAC will be critical to engagement of radiologists and implementation of reporting.
While additional studies are needed to determine the appropriate clinical response, the presence of BAC should at the minimum stimulate patient-provider conversations on lifestyle changes to mitigate cardiovascular risk, especially among younger women.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no external funding for the study. Co-first author TSA was supported by the National Heart, Lung, and Blood Institute (T32 HL079891-11) during the time of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All protocols were approved by the Institutional Review Board of UC San Diego Health (IRB #170154).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
ABBREVIATIONS
- BAC
- breast arterial calcification
- CVD
- cardiovascular disease
- AI
- artificial intelligence
- aHR
- adjusted hazard ratios
- ASCVD
- atherosclerotic cardiovascular disease
- FFDM
- full-field digital mammograms
- MI
- acute myocardial infarction
- HF
- heart failure
- SBP
- systolic blood pressure
- DBP
- diastolic blood pressure
- LDL
- low-density lipoprotein cholesterol
- CKD
- chronic kidney disease
- EMR
- electronic medical records
- UCSD
- University of California, San Diego
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos